Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$2.02 - $3.02 $246,137 - $367,987
121,850 Added 327.66%
159,038 $426,000
Q4 2023

Feb 14, 2024

BUY
$0.73 - $3.08 $27,147 - $114,539
37,188 New
37,188 $111,000
Q2 2023

Aug 14, 2023

SELL
$1.2 - $1.76 $5.71 Million - $8.37 Million
-4,755,321 Reduced 99.66%
16,039 $22,000
Q1 2023

May 15, 2023

BUY
$1.46 - $7.3 $1.96 Million - $9.8 Million
1,342,223 Added 39.14%
4,771,360 $7.59 Million
Q4 2022

Feb 14, 2023

BUY
$5.09 - $8.5 $13.4 Million - $22.4 Million
2,633,466 Added 330.97%
3,429,137 $21.4 Million
Q3 2022

Nov 14, 2022

BUY
$5.45 - $8.13 $4.27 Million - $6.37 Million
783,700 Added 6546.65%
795,671 $5.33 Million
Q2 2022

Aug 15, 2022

SELL
$4.77 - $6.67 $239,983 - $335,574
-50,311 Reduced 80.78%
11,971 $76,000
Q2 2020

Aug 14, 2020

SELL
$30.04 - $51.31 $5.99 Million - $10.2 Million
-199,456 Reduced 76.2%
62,282 $3.2 Million
Q1 2020

May 15, 2020

BUY
$27.44 - $73.84 $311,745 - $838,896
11,361 Added 4.54%
261,738 $8.25 Million
Q4 2019

Feb 14, 2020

BUY
$35.4 - $59.82 $4.08 Million - $6.89 Million
115,147 Added 85.15%
250,377 $14.9 Million
Q3 2019

Nov 14, 2019

SELL
$34.47 - $47.53 $903,734 - $1.25 Million
-26,218 Reduced 16.24%
135,230 $4.96 Million
Q2 2019

Aug 14, 2019

BUY
$40.1 - $52.33 $6.08 Million - $7.93 Million
151,554 Added 1531.78%
161,448 $7.51 Million
Q3 2018

Nov 14, 2018

SELL
$40.74 - $51.41 $1.28 Million - $1.61 Million
-31,330 Reduced 76.0%
9,894 $439,000
Q2 2018

Aug 14, 2018

SELL
$36.2 - $76.4 $3.95 Million - $8.34 Million
-109,217 Reduced 72.6%
41,224 $1.62 Million
Q1 2018

May 15, 2018

SELL
$65.94 - $80.76 $16.7 Million - $20.4 Million
-252,723 Reduced 62.68%
150,441 $10.9 Million
Q4 2017

Feb 14, 2018

BUY
$43.47 - $67.43 $435,308 - $675,244
10,014 Added 2.55%
403,164 $26.5 Million
Q3 2017

Nov 14, 2017

BUY
$43.8 - $52.77 $17.2 Million - $20.7 Million
393,150
393,150 $19.7 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $154M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.